- Home
- BIOA vs PLX Comparison
BIOA vs PLX Comparison
Compare BIOA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIOA
- PLX
- Stock Information
- Founded
- BIOA 2015
- PLX 1993
- Country
- BIOA United States
- PLX United States
- Employees
- BIOA N/A
- PLX N/A
- Industry
- BIOA Biotechnology: Pharmaceutical Preparations
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BIOA Health Care
- PLX Health Care
- Exchange
- BIOA Nasdaq
- PLX Nasdaq
- Market Cap
- BIOA 155.6M
- PLX 122.6M
- IPO Year
- BIOA 2024
- PLX 1998
- Fundamental
- Price
- BIOA $4.18
- PLX $1.47
- Analyst Decision
- BIOA Hold
- PLX Strong Buy
- Analyst Count
- BIOA 4
- PLX 1
- Target Price
- BIOA $5.67
- PLX $15.00
- AVG Volume (30 Days)
- BIOA 463.4K
- PLX 1.2M
- Earning Date
- BIOA 08-15-2025
- PLX 08-13-2025
- Dividend Yield
- BIOA N/A
- PLX N/A
- EPS Growth
- BIOA N/A
- PLX N/A
- EPS
- BIOA N/A
- PLX 0.05
- Revenue
- BIOA $1,451,000.00
- PLX $59,764,000.00
- Revenue This Year
- BIOA N/A
- PLX $65.02
- Revenue Next Year
- BIOA N/A
- PLX $57.34
- P/E Ratio
- BIOA N/A
- PLX $31.14
- Revenue Growth
- BIOA N/A
- PLX 0.18
- 52 Week Low
- BIOA $2.88
- PLX $0.82
- 52 Week High
- BIOA $26.62
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- BIOA N/A
- PLX 43.24
- Support Level
- BIOA N/A
- PLX $1.32
- Resistance Level
- BIOA N/A
- PLX $1.67
- Average True Range (ATR)
- BIOA 0.00
- PLX 0.11
- MACD
- BIOA 0.00
- PLX 0.03
- Stochastic Oscillator
- BIOA 0.00
- PLX 45.71
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.